Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

PaperCitations, authors & open-access status

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 582 citations, 2017 year and green oa status.

582
Citations
2017
Year
green
OA Status

Related on ScholarIQ

Alice T. Shaw
Author
Silvia Novello
Author
David R. Spigel
Author
Tae Min Kim
Author
Enriqueta Felip
Author
The Lancet Oncology
Journal
470M+ articles · free account